UNFPA have updated the list of medicines that are available for procurement based on a positive recommendation from the Expert Review Panel (ERP). There are currently five medicines on the list, including three oxytocics (misoprostol and mifepristone), one magnesium sulphate for the prevention and treatment of eclampsia, and one injectable contraceptive (norethisterone enanthate + estradiol valerate). The list of medicines and contact details for each product can be found here.
The ERP process was developed as an interim mechanism in cases when procurement of certain medicines is necessary and there are not enough reproductive health medicines available that are WHO prequalified or SRA approved. The ERP assesses the quality standards of the requesting manufacturers and decides whether or not to recommend procurement of the medicines in question for a period of 18 months. In some cases, this period may be extended for an additional 12 months after reassessment of a new submission of the product.
This process is a temporary solution to ensure access to quality medicines while suppliers undergo the WHO Prequalification Process. More information can be found on UNFPA’s website.